IASO Biotherapeutics announced receiving tacit clinical approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA)...
IASO Biotherapeutics announced that Fucaso (equecabtagene autoleucel injection), its proprietary fully human BCMA‑targeted CAR‑T cell...
IASO Biotherapeutics, a China‑based biotherapeutics developer, today announced a strategic collaboration agreement with GC Cell...
China‑based IASO Biotherapeutics and Shenzhen Cellbri Bio‑Innovation Technology Co., Ltd. announced a global strategic cooperation...
China-based IASO Biotherapeutics announced that its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Fucaso...
China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...
China-based IASO Biotherapeutics announced that the New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric...
IASO Biotherapeutics, a Chinese biotech firm, has received Investigational New Drug (IND) approval from the...
IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that the National Medical Products...
China-based IASO Biotherapeutics has announced that it has received Investigational New Drug (IND) approval from...
Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced a...
IASO Biotherapeutics, a biopharmaceutical company based in China, has announced that it has received tacit...
China-based IASO Biotherapeutics has received approval from the U.S. Food and Drug Administration (FDA) to...
China-based IASO Biotherapeutics has received clinical trial approval from the National Medical Products Administration (NMPA)...
IASO Biotherapeutics, a China-based company, and Umoja Biopharma, a California-headquartered developer of off-the-shelf cell therapies,...
Innovent Biologics, Inc. (HKG: 1801) and IASO Biotherapeutics have announced that they have received marketing...
China-based IASO Bio has announced that the US Food and Drug Administration (FDA) has approved...
China-based IASO Biotherapeutics has announced the completion of a nearly RMB 500 million (USD 73.7...